SCHEMBL3098649

SCHEMBL3098649

CC(Oc1ccc2nc(NC(=O)C3CC3)sc2c1)c1c(Cl)ccc(F)c1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
MET P08581 7/20 0.51
KIT P10721 2/20 0.51
FGFR2 P21802 2/20 0.51
AXL P30530 2/20 0.51
FLT3 P36888 2/20 0.51
MST1R Q04912 2/20 0.51
AURKA O14965 1/20 0.51
LCK P06239 1/20 0.51
FYN P06241 1/20 0.51
IGF1R P08069 1/20 0.51
EPHA2 P29317 1/20 0.51
LTK P29376 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3655887 0.89 MET (0.54) NPC1RAB9AMEN1KMT2AMET
SCHEMBL3105345 0.88 CASP3 (0.51) CASP3SENP8SENP7SENP6NPC1
SCHEMBL3791554 0.82 MET (0.45) METKITFGFR2AXLFLT3
SCHEMBL3657765 0.81 ATAD2 (0.48) NPC1RAB9AMEN1KMT2AMET
SCHEMBL3104528 0.81 MET (0.45) NPC1RAB9AKMT2AMETKIT
SCHEMBL3655253 0.81 ATAD2 (0.52) NPC1RAB9AMEN1KMT2A
SCHEMBL3102959 0.80 MET (0.51) METKITFGFR2AXLFLT3
SCHEMBL3110049 0.80 LCK (0.57) NPC1RAB9AMETKITFGFR2
SCHEMBL3652683 0.80 MET (0.43) NPC1RAB9AMETKITFGFR2
SCHEMBL3109971 0.80 PIK3CA (0.53) NPC1RAB9AMETKITFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed
EP-2205568-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS Sanofi-Aventis (FR) 2010-07-14 EP disclosed
WO-2009087305-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS SANOFI-AVENTIS (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 CASP3 3037/4885SENP8 3730/4885SENP7 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.